Stephen Silberstein, AAN 2019 – Advances in the prevention and treatment of migraine
US Neurology Editorial Board member, Stephen Silberstein (Thomas Jefferson University, Philadelphia, USA), discusses the most significant advances in the prevention and treatment of migraine in the last year.
- What do you consider the most important developments in migraine prevention and treatment in the last year? (0:04)
- What is the rationale for the use of anti epileptic drugs (AEDs) in the prevention and treatment of migraine? (0:49)
- Which AEDs do you recommend in the prevention of migraine and which might play a role in the future? (1:39)
- What is your opinion on the use of cannabinoids in the treatment of migraine? (2:13)
- What are the most exciting therapies currently in development in the field of migraine prevention and treatment? (3:19)
- Please summarize your highlights so far at this AAN meeting. (3:35)
Scientific Advisory Boards: Abide Therapeutics; Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Biohaven Pharmaceuticals; Cefaly; Curelator, Inc.; Dr. Reddy’s Laboratories; Egalet Corporation; GlaxoSmithKline Consumer Health Holdings, LLC; eNeura Inc.; electroCore Medical, LLC; Lilly USA, LLC; Medscape, LLC; NINDS; Satsuma Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; Theranica; and Trigemina, Inc.
Editorial Boards: Cephalalgia; Current Pain and Headache Reports; CNS Drugs; Topics in Pain Management; and Neurology.
Consultancies: Allergan; Amgen; eNeura; ElectroCore Medical; Mitsubishi Tanabe; Medtronic; Neuralieve; Pfizer; Supernus; and Teva.
Speakers’ Bureaus: Amgen; Teva; and Supernus.
Research Support, Commercial Entities (Past 2 years): GlaxoSmithKline; Allergan; Merck; Novartis; NIH; Neurolieve; MAP; Endo Now: Amgen; ElectroCore; Avanir; Allergan; Teva; and Lilly.
Research Support, Government Entities: NIH.
Research Support, Foundations and Societies: AHS and IHS.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Headache Disorders
Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]
Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]
Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!